

Characterization of the locomotor depression produced by an A_2 -selective adenosine agonist

Olga Nikodijević, John W. Daly and Kenneth A. Jacobson

Laboratories of Chemistry and Bioorganic Chemistry, National Inst. of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA

Received 26 December 1989; revised version received 27 December 1989

Adenosine analogs, such as N^6 -cyclohexyladenosine (CHA) that are selective for A_1 -adenosine receptors, and analogs, such as 5'- N -ethylcarboxamidoadenosine (NECA) that are active at both A_1 and A_2 receptors, cause a profound depression of locomotor activity in mice via a central mechanism. The depression is effectively reversed by non-selective adenosine antagonists such as theophylline. We report that 2-[(2-aminoethyl-amino)carbonyl-ethylphenylethylamino]-5'- N -ethylcarboxamidoadenosine (APEC), an amine derivative of the A_2 -selective agonist, CGS21680, is a potent locomotor depressant in mice. The *in vivo* pharmacology is consistent with A_2 -selectivity at a central site of action. Two parameters indicative of locomotor activity, horizontal activity and total distance travelled, were measured using a computerized activity monitor. From dose-response curves it was found that APEC (ED_{50} 16 μ g/kg) is more potent than CHA (ED_{50} 60 μ g/kg) and less potent than NECA (ED_{50} 2 μ g/kg). The locomotor depression by APEC was reversible by theophylline, but not by the A_1 -selective antagonists 8-cyclopentyltheophylline (CPT) and 8-cyclopentyl-1,3-dipropyl-2-thioxanthine, nor by the peripheral antagonists 8- p -sulfophenyltheophylline (8-PST) and 1,3-dipropyl-8- p -sulfophenylxanthine. The locomotor activity depression elicited by NECA and CHA was reversed by A_1 -selective antagonists. These results suggest that the effects of APEC are due to stimulation of A_2 adenosine receptors in the brain.


Adenosine analog; Locomotor depression; Adenosine receptor

1. INTRODUCTION

Adenosine, as a neuromodulator, inhibits the firing of neurons and the release of neurotransmitters in the central nervous system [1]. In behavioral models, adenosine agonists, acting via a central mechanism, cause a dramatic depression of locomotor activity, which is effectively reversed by the non-selective adenosine antagonists, caffeine and theophylline [2]. This effect has been demonstrated in rodents using a number of potent adenosine analogs, including the non-selective agonist, N -ethylcarboxamidoadenosine (NECA), and the A_1 selective agonists, N^6 -cyclohexyl- and N^6 -cyclopentyladenosine [3–5]. The potencies in producing hypomotility, as measured by head dipping and locomotor assays, of a series of adenosine agonists were recently found to correlate to the potencies of the analogs at A_2 receptors [6], suggesting that primarily A_2 receptors are involved in these effects. The lack of a truly A_2 -selective agonist has hampered these studies.

Recently, several classes of A_2 -selective adenosine agonists have been reported. N^6 -[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]adenosine [7] and 2-(carboxyethylphenylethylamino)adenosine-5'-carboxamide (CGS21680) [8,9] are A_2 -selective in competitive binding experiments at central A_1 - (measured in

cortex) and A_2 - (measured in striatum) adenosine receptors by factors of 32 and 140, respectively. CGS21680 was also shown to be A_2 -selective in the cardiovascular system [9]. CGS21680 contains a carboxylic acid functionality, which is expected to limit its passage across the blood/brain barrier [9]. Using a functionalized congener approach, a series of long-chain derivatives of CGS21680 that retain A_2 potency and selectivity and do not contain the carboxylic functionality, was synthesized [10]. An amine derivative, 2-[(2-aminoethyl-amino)carbonyl-ethylphenylethylamino]-5'-carboxamidoadenosine (APEC; 1), served as a synthetic intermediate for molecular probes for A_2 -adenosine receptors, including the first photo-affinity ligand, 125 I-PAPA-APEC [11]. We report that APEC, which is 17-fold A_2 -selective *in vitro* [10], is a potent locomotor depressant in mice. The *in vivo* pharmacology is consistent with A_2 -selectivity at a central site of action.



2. MATERIALS AND METHODS

2.1. Chemicals

NECA, CHA, 8-PST, CPT, DPSPX and XAC were obtained from Research Biochemicals, Inc. (Natick, MA). 2-Thio-CPX [13] was the

Correspondence address: O. Nikodijević, Laboratories of Chemistry and Bioorganic Chemistry, National Inst. of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA

generous gift of Professor W. Pfeleiderer (Univ. of Konstanz, FRG and Dr J. Neumeyer, RBI). CGS 21680C (Na salt) was the generous gift of Dr A. Hutchison (CIBA-Geigy Corp.). APEC was synthesized as described [10].

2.2. Animal studies

2.2.1. Subjects

Adult male mice of the NIH (Swiss) strain weighing 25–30 g were housed in groups of 12 animals per cage with a light-dark cycle of 12:12 h. The animals were given free access to standard pellet food and water and were habituated for 24 h in laboratory conditions prior to testing. Each animal was used only once in the activity monitor.

2.2.2. Locomotor activity

Individual animals were studied in a Digiscan activity monitor (Omnitech Electronics Inc., Columbus, OH) equipped with an IBM-compatible computer. Data was collected in the morning, for 3 consecutive intervals of 10 min each and analyzed as a group for 30 min sampling period. Two non-equivalent parameters [15] were analyzed: (i) horizontal activity, which represents the total number of beam interruptions in the horizontal direction; and (ii) total distance travelled, which indicates the distance in cm travelled by the animal. The latter is dependent on the path taken.

2.2.3. Drug administration

All drugs were dissolved in a 1:4 v/v mixture of Emulphor EL-620 (GAF Chemicals Corp., Wayne, NJ) and phosphate-buffered saline and administered i.p. in a vol. of 5 ml/kg b. wt. Warming and sonication aided in dissolving the drugs. When appropriate, an adenosine antagonist was injected first followed by an agonist after 10 min. Immediately after the final injection, the mouse was placed in the activity monitor cage, and data collection was begun after a delay of 10 min. Statistical analysis was performed using the Student's *t*-test. Each value reported represents the mean $\pm$ SE for 6–10 animals, except for the control points (vehicle injected) for which $n = 22$.

3. RESULTS

The locomotor effects at different doses of APEC and the adenosine agonists NECA and CHA, administered intraperitoneally in mice, were measured. The dose-response curves are given in fig.1. APEC was found to have an ED₅₀ value for horizontal activity of 14 μ g/kg b. wt. Thus, APEC is more potent than CHA (ED₅₀ = 70 μ g/kg) and less potent than NECA (ED₅₀ = 2 μ g/kg). CGS21680 was also tested as a locomotor depressant at several doses. CGS21680 at a dose of 16 μ g/kg^a was nearly inactive with $3 \pm 0.2\%$ and $13 \pm 1\%$ depression of horizontal activity (h.a.) and total distance travelled (t.d.), respectively. At a dose of 1 μ mol/kg, CGS21680 caused decreases of $64 \pm 4.5\%$ (h.a.) and $62 \pm 5\%$ (t.d.) in locomotor activity, and at 3 μ mol/kg the locomotor depression was $94 \pm 9\%$ (h.a.) and $96 \pm 20\%$ (t.d.).

The locomotor depressant activity of APEC was not reversed by the peripheral adenosine antagonist, 8-*p*-sulfophenyltheophylline (8-PST; fig.2). This is consistent with a central mechanism for the locomotor




Fig.1. Dose-response curves for locomotor depression in mice by the adenosine agonists, NECA (squares), APEC (triangles) and CHA (circles). For each analog, percent decrease compared to vehicle control is shown for horizontal activity (open symbols) and total distance (closed symbols).

depression by APEC. Similarly, the more potent 1,3-dipropyl-8-(*p*-sulfophenyl)xanthine (DPSPX) at 5 mg/kg did not antagonize APEC (fig.2). Since 8-PST and DPSPX are relatively non-selective, a peripheral action at either A₁ or A₂ subtypes is precluded as the mechanism for the locomotor depression by APEC. Curiously, at high doses, these peripheral antagonists both elicited some locomotor depression. This depression is particularly evident in the effect of 10 mg/kg 8-PST on total distance travelled ($24 \pm 2\%$ decrease). At 5 mg/kg the depressant effect on total distance travelled was $6 \pm 0.5\%$ and $12 \pm 1.8\%$ for 8-PST and




Fig.2. The effects of the peripheral adenosine antagonists, 8-PST and DPSPX, on locomotor depression induced by APEC (16 μ g/kg). Changes in horizontal activity (solid bars) and total distance travelled (hatched bars), relative to vehicle control, are shown.

^a The dose equal to the average of ED₅₀ values for APEC for horizontal activity and total distance (corresponds to 0.03 μ mol/kg APEC).

DPSPX, respectively. The A_1 -selective antagonist, 2-thioCPX (see below), depressed locomotor activity only at a dose of 10 mg/kg, with decreases of $23 \pm 3\%$ (h.a.) and $28 \pm 3.6\%$ (t.d.). The mechanisms underlying such depressant effects are unclear. At a dose of 10 mg/kg 8-(*p*-sulfophenyl)caffeine, which is structurally related to 8-PST but inactive or weakly active, respectively, as an adenosine antagonist at A_1 and A_2 receptors [16], stimulated locomotor activity slightly by $6 \pm 0.2\%$ (h.a.) and $12 \pm 1.8\%$ (t.d.).

The A_1 -selective antagonist, 8-cyclopentyltheophylline (CPT), has been reported to antagonize the central depressant activities of adenosine agonists, such as N^6 -cyclopentyladenosine [4]. Similarly, we found that CPT could reverse the depression by an ED_{50} dose of CHA (fig.3), an agonist that is A_1 -selective by a factor of 390 [12]. The depression evoked by an ED_{50} dose of NECA, an agonist that has marked activity at both adenosine receptor subtypes, was also completely reversed by this A_1 -selective antagonist (fig.4). However, the locomotor depression evoked by APEC was not reversible by a comparable dose of CPT (fig.4). This suggests that the depressant effect of APEC is due to stimulation of A_2 adenosine receptors in the brain. The depressant effects of APEC were reversed by the




Fig.3. The effects of the A_1 -selective adenosine antagonist, CPT, on locomotor depression induced by CHA (60 μ g/kg). Percent changes in total distance travelled (A) and horizontal activity (B), relative to vehicle control, are shown.




Fig.4. The effects of an A_1 -selective antagonist on locomotor depression induced by adenosine 5'-carboxamide analogs. The percent change in locomotor activity, relative to vehicle control, induced by NECA (2 μ g/kg) and APEC (16 μ g/kg) at the ED_{50} doses, in the presence (hatched bars) and absence (solid bars) of 10 mg/kg CPT, is shown.

non-selective antagonist theophylline. At the ED_{50} dose of APEC, 10 mg/kg theophylline restore the total distance travelled to $95 \pm 12\%$ of control.

In contrast to PST, DPSPX and 2-thio-CPX at high doses, CPT alone at 10 mg/kg was found to be a weak central stimulant (fig.3) causing increases of $41 \pm 8\%$ and $24 \pm 7\%$ for total distance travelled and horizontal activity, respectively. This finding is in contrast to a previous report [4] in which no stimulation by CPT (up to 30 mg/kg) was seen. To further study the effects of A_1 -selective adenosine antagonists on the locomotor depression by APEC, we searched for another centrally active A_1 -selective xanthine. The potent ($K_i = 0.66$ nM) and 480-fold A_1 -selective antagonist, 8-cyclopentyl-1,3-dipropyl-2-thioxanthine (2-thio-CPX) [13,14], was shown to reverse the locomotor depression elicited by CHA (data not shown). At a dose of 5 mg/kg, 2-thio-CPX alone, unlike CPT, did not appreciably stimulate locomotor activity (increases of $1 \pm 0.1\%$ in both h.a. and t.d.). Like CPT, this xanthine failed to antagonize the locomotor effects of APEC, further supporting the conclusion of in vivo A_2 selectivity of APEC. A combination of 5 mg/kg 2-thio-CPX and the ED_{50} dose of APEC depressed locomotor activity by $50 \pm 10\%$ (h.a.) and $55 \pm 13\%$ (t.d.).

4. DISCUSSION

The results show that APEC, previously determined to be A_2 -selective in binding assays at rat brain adenosine receptors [10], is a potent locomotor depressant in mice. The dose-response curves and the ED_{50} values for the effects of adenosine agonists on two parameters indicative of locomotor activity (horizontal

activity and total distance travelled; fig.1) show an order of potency of NECA > APEC > CHA. CHA ($K_i = 10$ nM) is also less potent than NECA and APEC ($K_i = 10.3$ and 5.73 nM, respectively) in competitive binding experiments at A_2 adenosine receptors [10,12]. The locomotor effects of APEC were not reversed by the A_1 -selective adenosine antagonists, CPT and 2-thio-CPX. Both of these xanthines are centrally active antagonists and both reverse the locomotor depression elicited by the A_1 agonist, CHA. Moreover, the effect of the non-selective antagonist, theophylline, and the inactivity of peripheral, non-selective antagonists, PST and DPSPX, in reversing locomotor depression elicited by APEC suggests central action at adenosine receptors. The lack of antagonism of APEC-elicited depression by the A_1 -selective xanthines, CPT and 2-thio-CPX, strongly suggests that activation of A_2 receptors are involved in the behavioral depression. Prior studies have suggested that activation of either A_1 or A_2 receptors can elicit dramatic depressant effects [2–6]. APEC now provides an important tool for investigation of the role of central A_2 receptors, just as the A_1 -selective agonists, CHA and CPA, provide tools for investigation of the role of central A_1 receptors.

CGS21680, the structural precursor of APEC, has been evaluated as a potentially therapeutic, hypotensive agent [9]. The charged carboxylate group is predicted to tend to restrict the action of this potent and highly selective A_2 adenosine agonist ($K_i = 14$ nM) to the periphery [8]. It is possible that the reason for the behavioral inactivity of CGS21680 at a low dose, at which APEC is active, is due to diminished passage across the blood/brain barrier. At higher doses, CGS21680 acts as a locomotor activity depressant, but less potent than CHA. The aliphatic amino group of APEC is predominantly but not completely charged at physiological pH, which obviously does not prevent its entry into the CNS.

Yet to be resolved is why NECA is much more potent than APEC despite similar affinity at A_2 -receptors. In addition to pharmacokinetic factors, there remains the possibility that dual activation of A_1 and A_2 receptors by NECA is acting synergistically on locomotor depression. The blockade by CPT of NECA-elicited

behavioral depression [4] suggests a key role for A_1 receptors, yet other data [3] suggests that A_2 receptors are involved. Preliminary results (unpublished) suggest that the effects of APEC and CHA are more than additive, supporting possible synergistic interactions of A_1 and A_2 receptors in eliciting behavioral depression.

REFERENCES

- [1] Snyder, S.H. (1985) *Annu. Rev. Neurosci.* 8, 103–124.
- [2] Snyder, S.H., Katims, J.J., Annau, Z., Bruns, R.F. and Daly, J.W. (1981) *Proc. Natl. Acad. Sci. USA* 78, 3260–3264.
- [3] Seale, T., Abia, K.A., Shamim, M.T., Carney, J.M. and Daly, J.W. (1988) *Life Sci.* 43, 1671–1684.
- [4] Bruns, R.F., Davis, R.E., Ninteman, F.W., Poschel, B.P.H., Wiley, J.N. and Heffner, T.G. (1988) in: *Physiology and Pharmacology of Adenosine and Adenine Nucleotides* (Paton, D.M. ed.) pp.39–49, Taylor and Francis, London.
- [5] Heffner, T.G., Wiley, J.N., Williams, A.E., Bruns, R.F., Coughenour, L.L. and Downs, D.A. (1989) *Psychopharmacology* 98, 31–37.
- [6] Durcan, M.J. and Morgan, P.F. (1989) *Eur. J. Pharmacol.* 168, 285–290.
- [7] Bridges, A.J., Bruns, R.F., Ortwine, D.F., Priebe, S.R., Szotek, D.L. and Trivedi, B.K. (1988) *J. Med. Chem.* 31, 1282–1285.
- [8] Hutchison, A.J., Williams, M., DeJesus, R., Oei, H.H., Ghai, G.R., Webb, R.L., Zoganas, H.C., Stone, G.A. and Jarvis, M.F. (1989) *J. Med. Chem.*, in press.
- [9] Hutchison, A.J., Webb, R.L., Oei, H.H., Ghai, G.R. and Williams, M. (1989) *J. Pharm. Exp. Ther.* 251, 47–55.
- [10] Jacobson, K.A., Barrington, W.W., Pannell, L.K., Jarvis, M.F., Ji, X.-D., Hutchison, A.J. and Stiles, G.L. (1990) *J. Mol. Recognition*, in press.
- [11] Barrington, W.W., Jacobson, K.A., Williams, M., Hutchison, A.J. and Stiles, G.L. (1989) *Proc. Natl. Acad. Sci. USA* 86, 6572–6576.
- [12] Bruns, R.F., Lu, G.H. and Pugsley, T.A. (1986) *Mol. Pharmacol.* 29, 331–346.
- [13] Jacobson, K.A., Kiriasis, L., Barone, S., Bradbury, B.J., Kammula, U., Campagne, J.M., Secunda, S., Daly, J.W. and Pfeleiderer, W. (1989) *J. Med. Chem.* 32, 1873–1879.
- [14] Neumeyer, J.L., De la Cruz, D., Kiriasis, L., Barone, S., Bradbury, B.J., Kammula, U., Campagne, J.M., Secunda, S., Daly, J.W., Pfeleiderer, W. and Jacobson, K.A. (1989) Abstract B-16, Purine Nucleosides and Nucleotides in Cell Signalling: Targets for New Drugs (meeting), Sept. 1989.
- [15] Sandberg, P.R., Hagenmeyer, S.H. and Henault, M.A. (1985) *Neurobehav. Toxicol. Teratol.* 7, 87–94.
- [16] Shamim, M.T., Ukena, D., Padgett, W.L. and Daly, J.W. (1989) *J. Med. Chem.* 32, 1231–1237.